USO Stock News US Oil (USO) 36.19 08/01/2014 22:05:31

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
US Oil (USO) 36.19 $USO

SmarTrend Watching for Potential Rebound in Shares of United States Oil Fund After 1.26% Loss
Comtex SmarTrend(R) - Wed Jul 30, 4:37PM CDT
United States Oil Fund (AMEX:USO) traded in a range yesterday that spanned from a low of $36.85 to a high of $37.68. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $37.20 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

United States Oil Fund Falls 1.26% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Jul 30, 4:37PM CDT
United States Oil Fund (AMEX:USO) traded in a range yesterday that spanned from a low of $36.85 to a high of $37.68. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $37.20 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Look for Shares of United States Oil Fund to Potentially Pullback after Yesterday's 1.01% Rise
Comtex SmarTrend(R) - Mon Jul 21, 4:23PM CDT
United States Oil Fund (AMEX:USO) traded in a range yesterday that spanned from a low of $37.77 to a high of $38.16. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $37.91 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

United States Oil Fund Set to Possibly Pullback After Yesterday's Rally of 1.01%
Comtex SmarTrend(R) - Mon Jul 21, 4:23PM CDT
United States Oil Fund (AMEX:USO) traded in a range yesterday that spanned from a low of $37.77 to a high of $38.16. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $37.91 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why Is USO -- the Oil ETF -- Outperforming the Price of Oil?
at The Street - Fri Jul 18, 5:00AM CDT
Developments in the oil futures markets led United States Oil to outperform its sector. Let's look at why.

Look for Shares of United States Oil Fund to Potentially Rebound after Yesterday's 1.18% Sell Off
Comtex SmarTrend(R) - Tue Jul 15, 5:22PM CDT
United States Oil Fund (AMEX:USO) traded in a range yesterday that spanned from a low of $36.58 to a high of $36.94. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $36.96 on volume of 4.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

What Happened To My Energy Portfolio?
Oilprice.com, The Motley Fool - Motley Fool - Tue Jul 15, 10:41AM CDT
This article was written by  Oilprice.com  -- the leading provider of energy news in the world. Also c heck out these recent articles: If you have asked yourself the question, "What happened to my energy portfolio?" over the...

Guide to Oil Commodity ETFs - ETF News And Commentary
Sweta Killa - ZACKS - Thu Jul 10, 1:00PM CDT
Oil ETFs could be an interesting play for investors looking to tap the recent beaten down price of oil.

Oil Prices Supported by Middle East, Ukraine Events, Not Fundamentals
at The Street - Mon Jul 07, 12:27PM CDT
Geopolitical conflict in the Middle East and Ukraine led to the spike higher in oil prices. Conflict resolution could send prices lower.

Watch for United States Oil Fund to Potentially Rebound After Falling 1.18% Yesterday
Comtex SmarTrend(R) - Wed Jul 02, 4:41PM CDT
United States Oil Fund (AMEX:USO) traded in a range yesterday that spanned from a low of $38.39 to a high of $38.91. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $38.57 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Coal, Peabody Energy Are Bullish in the Long Term -- Here's Why
at The Street - Tue Jul 01, 12:21PM CDT
Profit from coal is down but not out.

Top ETF Stories of June - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Tue Jul 01, 12:00PM CDT
Significant domestic and international developments have attracted investor attention into the ETF world last month. Let's see what these striking stories were.

Do Geopolitics Still Have a Firm Hold on Commodities, Oil, Gold?
at The Street - Fri Jun 27, 12:33PM CDT
Middle Eastern tensions might seem bullish for oil. But there are other factors to consider for commodities investors.

Iraq Ignites Gasoline ETF - ETF News And Commentary
Sweta Killa - ZACKS - Tue Jun 24, 12:00PM CDT
Gasoline ETF is climbing higher on Iraq tensions, refinery maintenance, growing demand and a favorable futures curve.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 9

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 123

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 52

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 422

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 175

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 104

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 0

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 432

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading

Top 5 Most Recently Viewed Articles

NKGen Biotech to Present Innovative Research at Global Congress

Updated Category News Views 157

NKGen Biotech's Exciting Announcement on Upcoming Presentation NKGen Biotech Inc. (NASDAQ: NKGN), a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge autologous and allogeneic natural killer cell therapies, has recently shared some thrilling news regarding their participation in an international event. Highlighting Neurodegenerative...

Continue Reading
Celebrating Case Managers: A Call to Action for 2025

Updated Category News Views 522

Recognizing the Contribution of Case Managers in 2025 Case managers have proven time and again to be essential contributors to the health and human services spectrum. In 2025, the two prominent organizations in the case management field—the American Case Management Association (ACMA) and the Commission for Case Manager Certification (CCMC)—have once again partnered to...

Continue Reading
Faruqi & Faruqi Investigates Ford Investor Claims

Updated Category News Views 92

Back in 2024, Faruqi & Faruqi took aim at Ford Motor Company (NYSE: F), investigating claims from investors who’d racked up losses over $100,000. They were diving deep into the financial mess at Ford—a colossal vehicle manufacturer that found itself knee-deep in allegations of breaching federal securities laws. The chatter was all about how quality assurance failures...

Continue Reading
Entourage Health Announces Going-Private Arrangement Plan

Updated Category News Views 236

Entourage Health Corp. Takes a Bold Step Toward Going-Private Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) has officially entered into a significant arrangement agreement with 1001007762 Ontario Inc. and 2437653 Ontario Inc. This strategic move, a statutory plan under the Business Corporations Act (Ontario), sees the Purchaser agreeing to acquire all common shares...

Continue Reading
A&W Revenue Royalties Income Fund Q3 2024 Results Review

Updated Category News Views 183

A&W Revenue Royalties Income Fund Q3 2024 Financial Overview TRADING SYMBOL: TSX: AW.UN A&W Revenue Royalties Income Fund has reported encouraging results for the third quarter ending this year. The quarterly performance reflects steady royalty income growth and strategic developments that promise an exciting future. Royalty Income Performance In the third quarter of...

Continue Reading